Zymeworks (ZYME) to Release Quarterly Earnings on Thursday

Zymeworks (NASDAQ:ZYME) is expected to announce its Q1 2026 results after the market closes on Thursday, May 7th. Analysts expect the company to announce earnings of ($0.10) per share and revenue of $24.3760 million for the quarter. Investors can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Thursday, May 7, 2026 at 4:30 PM ET.

Zymeworks (NASDAQ:ZYME) last announced its quarterly earnings data on Saturday, February 14th. The company reported ($0.55) earnings per share (EPS) for the quarter. The firm had revenue of $2.52 million for the quarter. Zymeworks had a negative net margin of 76.56% and a negative return on equity of 26.00%. On average, analysts expect Zymeworks to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Zymeworks Stock Down 0.7%

Shares of NASDAQ:ZYME traded down $0.18 during trading on Tuesday, hitting $26.60. 264,725 shares of the company traded hands, compared to its average volume of 707,495. The stock has a market capitalization of $1.96 billion, a price-to-earnings ratio of -24.62 and a beta of 1.20. The business’s fifty day moving average is $25.39 and its 200-day moving average is $23.88. Zymeworks has a one year low of $10.86 and a one year high of $29.75.

Hedge Funds Weigh In On Zymeworks

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Rubric Capital Management LP grew its holdings in Zymeworks by 22.1% in the 4th quarter. Rubric Capital Management LP now owns 5,750,000 shares of the company’s stock worth $151,398,000 after buying an additional 1,039,449 shares in the last quarter. Vestal Point Capital LP grew its holdings in Zymeworks by 53.5% in the 3rd quarter. Vestal Point Capital LP now owns 1,765,000 shares of the company’s stock worth $30,146,000 after buying an additional 615,000 shares in the last quarter. Siren L.L.C. bought a new position in Zymeworks in the 4th quarter worth approximately $44,238,000. Deutsche Bank AG grew its holdings in Zymeworks by 3.3% in the 4th quarter. Deutsche Bank AG now owns 1,595,833 shares of the company’s stock worth $42,018,000 after buying an additional 50,935 shares in the last quarter. Finally, Millennium Management LLC grew its holdings in Zymeworks by 851.6% in the 3rd quarter. Millennium Management LLC now owns 1,104,813 shares of the company’s stock worth $18,870,000 after buying an additional 988,711 shares in the last quarter. 92.89% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the company. Truist Financial raised Zymeworks to a “strong-buy” rating in a report on Monday, April 27th. HC Wainwright upped their target price on Zymeworks from $32.00 to $46.00 and gave the company a “buy” rating in a report on Friday, March 6th. Stifel Nicolaus upped their target price on Zymeworks from $40.00 to $47.00 and gave the company a “buy” rating in a report on Tuesday, March 3rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zymeworks in a report on Monday, April 20th. Finally, Leerink Partners upped their target price on Zymeworks from $52.00 to $58.00 and gave the company an “outperform” rating in a report on Tuesday, March 3rd. Two research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $37.89.

About Zymeworks

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. The company specializes in engineered antibody and protein therapeutics designed to address a range of unmet medical needs in oncology and other serious diseases. Through its proprietary platforms, Zymeworks aims to create novel bispecific and multispecific molecules that can simultaneously engage multiple targets and recruit immune effector functions to enhance potency and specificity.

At the core of Zymeworks’ innovation is its Azymetric™ bispecific antibody platform, which enables the design of asymmetrical bispecific antibodies with controlled assembly and high stability.